Lyprinol—Is It a Useful Anti-Inflammatory Agent? by Doggrell, Sheila A.
Hindawi Publishing Corporation
Evidence-Based Complementary and Alternative Medicine
Volume 2011, Article ID 307121, 7 pages
doi:10.1093/ecam/nep030
Review Article
Lyprinol—IsIt a UsefulAnti-Inﬂammatory Agent?
SheilaA.Doggrell
School of Life Sciences, Queensland University of Technology, GPO Box 2434, Brisbane, QLD4001, Australia
Correspondence should be addressed to Sheila A. Doggrell, sheila.doggrell@qut.edu.au
Received 25 September 2008; Accepted 25 March 2009
Copyright © 2011 Sheila A. Doggrell. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The New Zealand green lipped mussel preparation Lyprinol is available without a prescription from a supermarket, pharmacy or
Web. The Food and Drug Administration have recently warned Lyprinol USA about their extravagant anti-inﬂammatory claims
for Lyprinol appearing on the web. These claims are put to thorough review. Lyprinol does have anti-inﬂammatory mechanisms,
andhasanti-inﬂammatoryeﬀectsinsomeanimalmodelsofinﬂammation.Lyprinolmayhavebeneﬁtsindogswitharthritis.There
are design problems with the clinical trials of Lyprinol in humans as an anti-inﬂammatory agent in osteoarthritis and rheumatoid
arthritis, making it diﬃcult to give a deﬁnite answer to how eﬀective Lyprinol is in these conditions, but any beneﬁt is small.
Lyprinol also has a small beneﬁt in atopic allergy. As anti-inﬂammatory agents, there is little to choose between Lyprinol and ﬁsh
oil. No adverse eﬀects have been reported with Lyprinol. Thus, although it is diﬃcult to conclude whether Lyprinol does much
good, it can be concluded that Lyprinol probably does no major harm.
1.Introduction
The New Zealand green lipped mussel preparation Lyprinol
is readily available without a prescription from a supermar-
ket, pharmacy or web. Over the years, “Miracle from the sea”,
andmanyotherclaimshavebeenmadeaboutthetherapeutic
beneﬁts of Lyprinol [1]. In 1999, there was the extraordinary
situation of Lyprinol being promoted and marketed as an
anti-cancer agent [2]. As a consequence, patients bought
large quantities of this product at signiﬁcant expense (NZ$2
million), despite there being no evidence of eﬃcacy [3].
TheTherapeuticsGoodsAdministrationinAustraliaadvised
cancerpatientsnottorelyonthissubstanceforthetreatment
of their cancer, and to seek medical advice.
More recently, Lyprinol has been promoted for its anti-
inﬂammatory eﬀects. The starting point for the interest in
the green lipped mussel as therapy for inﬂammation was
folklore.ThisfolklorewasthatcoastaldwellingMaoriinNew
Zealand, who regularly consumed mussels as part of their
diet, suﬀered far less from the ravages of arthritis than their
inland dwelling relatives [1].
The trade mark for Lyprinol is held by Pharmalink,
who state that “Lyprinol has been usefully for the treatment
of osteoarthritis, rheumatoid arthritis, asthma and gout
and is being studied for its eﬀectiveness against the other
inﬂammatory diseases such as Crohn’s disease, ulcerative
colitis, lupus, psoriasis and others” [4]. Lyprinol is marketed
on the net by NZ Nutraceuticals, which states it has
“clinically proven anti-inﬂammatory properties”, and that
“as an eﬀective anti-inﬂammatory agent, Lyprinol is used to
treat arthritis, osteoarthritis, rheumatoid arthritis, asthma,
muscle pain (particularly for sports people)” [5]. Lyprinol
is marketed in Australia by Blackmores, and the packet
states “Its potent anti-inﬂammatory actions assist in the
maintenance of healthy airways and breathing passages, as
well as providing relief from joint swelling and arthritis.”
As recently as 2007, The Food and Drug Adminis-
tration warned LyprinolUSA about their extravagant anti-
inﬂammatory claims for Lyprinol appearing on the web
[6]. LyprinexTM also contains Lyprinol and is marketed
internationally, including on the web by Life Plus Interna-
tional [7]. LyprinexTM claimed “Lyprinol has been shown
to improve the following conditions: Inﬂammation; Pain
duetoinﬂammation;Bronchialtightness;Allergysymptoms.
Additional beneﬁts: (Lyprinol) May lower depression: May
reduce the risk of coronary heart disease. It (Lyprinol)
improvestheconditionofpatientswithrheumatoidarthritis:
it improves the condition of patients with asthma [7].”
There were some initial problems with extracting the
ingredients from Perna canaliculus, the NZ green lipped
mussel, as most of the activity was lost with heat treatments
or freeze drying [1]. Thus, some of the early studies may
have been carried out with preparations with no active
ingredients, and (not surprisingly), an anti-inﬂammatory2 Evidence-Based Complementary and Alternative Medicine
action was not consistently reported [1]. The process now
being used to extract the ingredients from the mussels
does result in Lyprinol having active ingredients [8]. As
these extraction problems were sorted out by 1990, only
publications from 1990 onwards are considered in this
review. In addition to Lyprinol (also known as Seatone) and
products derived from Lyprinol, Perna (the lyophilized P.
canaliculus powder) is active, and is discussed in this review.
Mobicosa is a new freeze-dried preparation of the green
lipped mussel which in addition to the fatty acids reported
in Lyprinol (see Section 2) contains other natural agents
(glucosamines and chrondroitin sulphates) [9]. These com-
pounds have been claimed to have beneﬁts in arthritis in
their own right. Consequently, it is diﬃcult to determine
whether any beneﬁts of Mobicosa are due to the fatty acids
in the P. canaliculus, or the glucosamines and chrondroitin.
For this reason, and also because, to my knowledge, there
are no published studies of the eﬀects of Mobicosa in clinical
trials in animals or humans, Mobicosa is not included in this
review.
This review is a thorough review of Lyprinol as an anti-
inﬂammatory agent. Pubmed and the Internet were searched
for references to Lyprinol, Seatone and Perna alone, avail-
able from 1990 onwards. In the ﬁrst part of the review,
the anti-inﬂammatory mechanisms of actions of Lypri-
nol/Seatone/Perna are discussed. This is followed by a review
of the evidence for anti-inﬂammatory eﬀects with Lypri-
nol/Seatone/Perna in animal models. The major emphasis
of this review is the clinical trials with Lyprinol, which
are critically discussed. Fish oil is another complementary
medicine that is used as an anti-inﬂammatory agent. Fish
oil has some of the same ingredients as Lyprinol, and
the ﬁnal part of the review considers studies that have
compared ﬁsh oil and Lyprinol as anti-inﬂammatory agents.
T h es e a r c hw o r d sf o rt h i sﬁ n a lp a r to ft h er e v i e wa r eﬁ s h
oil and Lyprinol/Seatone/Perna and inﬂammation or anti-
inﬂammatory.
2. Contents of Lyprinol
Lyprinol is a mixture of the ﬁve main lipid classes including
s t e r o le s t e r s ,t r i g l y c e r i d e s ,f r e ef a t t ya c i d s ,s t e r o l sa n dp o l a r
lipids [1]. Lyprinol contains two of the long chain omega-3
polyunsaturated fatty acids (PUFAs); eicosapentaenoic acid
(EPA) and docosahexaenoic acid (DHA) [1]. In amounts,
Lyprinol is 13% EPA, 21% DHA and about 30% cholesterol
[10]. Additionally, Lyprinol contains some novel ω-3 PUFAs;
5,9,12,15-octodecatretraenoic acid, 5,9,12,16-nondecatert-
raenoic acid, 7,11,14,17-eicosatetraenoic acid, and 5,9,12,
15,18-heneicsapententaenoic acid [11]. EPA and DHA are
the main ingredients of ﬁsh oil supplements. Thus, there
will be similarities between Lyprinol and ﬁsh oil, which are
discussed later in this review.
EPA, DHA and the ω-3 PUFA 7,11,14,17-eicosatetrae-
noic acid are similar in structure to arachidonic acid (5,8,11,
14-eicosatraenoic acid), the precursor to the inﬂammatory
agents, prostaglandins and leukotrienes. Thus, it is probably
not surprising that Lyprinol can modulate the eﬀects of these
inﬂammatory agents to exert an anti-inﬂammatory eﬀect.
3. Anti-Inﬂammatory Mechanismsof
Action of Lyprinol
As competitive substrates for the cyclooxygenase enzyme
(COX; synthesis of prostaglandins) and the lipoxygenase
enzyme(synthesisofleukotrienes),EPAandDHAreducethe
levels of the inﬂammatory prostaglandins and leukotrienes.
Lyprinolalsodoesthis,presumably(atleastpartly)duetothe
EPA and DHA content. In human monocytes, PGE2 produc-
tion from arachidonic acid was inhibited by Lyprinol with an
IC50 of 1.2μgmL −1 [12]. With human polymorphonuclear
leukocytes in the presence of arachidonic acid, Lyprinol
(100μgmL −1) abolished the formation of leukotrienes (LT)
B4 and reduced the formation of 5-HETE (products from
the lipooxygenase pathways) [12] .T h ef r e ef a t t ya c i d sf r o m
Lyprinol have also been shown to inhibit the formation of
LTB4 and 5-HETE from human neutrophils stimulated with
arachidonic acid and a calcium ionophore [11].
Lyprinol also has a direct ability to inhibit the COX
enzymes (COX-1 and COX-2) [13]. COX-2 is the inducible
enzyme commonly associated with excessive inﬂammation.
Thus, P. canaliculus at 1μgmL −1 inhibited COX-1 and COX-
2 by 12% and 25%, respectively [13]. After hydrolysis to the
free fatty acid fraction, inhibition was increased to 49% for
COX-1 and 60% for COX-2, and when the free fatty acids
were separated, inhibition was increased further to 78% for
COX-1 and 70% for COX-2 [13]. Both the Tween-20 extract
and the glycogen extract of Perna (Aroma NZ Ltd), which is
lyophilized P. canaliculus powder, have been shown to inhibit
COX-1 and COX-2 [14].
In addition to prostaglandins and leukotrienes, his-
tamine and cytokines are mediators of inﬂammation. In
1986, there was a brief report of anti-histaminic activity with
P. canaliculus [15]. Recently, Lyprinol has been shown to
decrease the ability of lipopolysaccharide (LPS) to stimu-
late tumour necrosis factor-alpha (TNF-α) and interferon-
gamma (IFN-γ) in splenocytes from a rat model of arthritis,
where Freund’s complete adjuvant containing Mycobactrium
butyricum was injected into the paw [16] .T h el e v e l so fT N F -
α and IFN-γ were raised in untreated arthritis to 3.1 and
10.7ngmL−1, and after Lyprinol treatment were decreased
to 1.71 and 3.0mgmL−1,r e s p e c t i v e l y[ 16].
Perna has also been shown to reduce the concentrations
of TNF-α and interleukin (IL)-12p40 production from LPS
stimulated human THP-1 monocytes [17]. In addition to
inhibiting TNF-α, Tween-20 extracts of Perna have been
shown to inhibit the production of IL-1, IL-2 and IL-6 in
isolated cell preparations, and also to inhibit IgG production
[14].
Recently, proteomics in the splenocytes from the rat
model of arthritis induced by M. butyricum has shown
changes in protein expression with Lyprinol, but it is not
clear whether these changes relate to the anti-inﬂammatory
eﬀect of Lyprinol. Thus, Lyprinol changed the expression
of several proteins related to metabolism (increased expres-
sion of malate dehydrogenase, and decreased expression of
protein-o-mannosyl-transferase2,titin-capprotein,andpro-
tein disulﬁde isomerase) and decreased expression of Tdrd7,
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these changes in proteins related to metabolism may be
responsible for the anti-inﬂammatory eﬀects of Lyprinol.
Manyfurtherexperimentsarerequiredtotestthishypothesis
including testing whether Lyprinol alters the expression of
these proteins in other models of inﬂammation, and what, if
any, is the relationship between these proteins and the anti-
inﬂammatory eﬀects of Lyprinol.
4. Lyprinolin AnimalModels of Arthritis
4.1. Carrageenan Model. In one of the standard models of
arthritis used in experimental studies of arthritis, the injec-
tion of carrageenan into rear paws of rats to induce swelling,
Lyprinol showed little activity [12]. However, Lyprinol has
been shown to reduce swelling in other animal models of
arthritis.
4.2. Collagen Type-II-Induced Arthritis. Collagen type-II-
induced arthritis is another established animal model of
human arthritis, and in this model, Lyprinol does suppress
inﬂammation [12]. In this model, the collagen is emulsiﬁed
with complete Freund’s adjuvant and injected into the rear
right paw of the rat [12]. The amounts of paw swelling
were 1.77 and 1.62mm in the rear left and right rear paws,
respectively, and this was reduced to 0.32 and 1.04mm
with Lyprinol (20mgkg−1) and to 0.82 and 1.48mm with
ibuprofen (50mgkg−1)[ 12].
Glucocorticoids are the standard treatment of severe
arthritis, and when new drugs are developed for arthritis,
they are compared to the glucocorticoids, as only if agents
canbeshowntobebetteroradditivewithglucocorticoidsare
they likely to have a role in clinical practice. When collagen
type-II in Freund’s incomplete adjuvant was used to induce
arthritis in rats, Lyprinol at 20mgkg−1 had no eﬀect alone
on paw swelling, nor did the glucocorticoid prednisone at
2.5mgkg−1 alone [19]. However, when these agents were
combined, at the same doses, the paw swelling was reduced
[19]. Key studies comparing Lyprinol to an eﬀective dose of
glucocorticoid, or with an eﬀective dose of glucocorticoid,
have not been reported in this standard model or arthritis.
Pernahasalsobeentestedinthecollagentype-II-induced
severe polyarticular arthritis model in the rat and mouse
[17]. In the rat, when Perna 100mgkg−1 day−1 treatment
was started at the same time as the collagen type II, there
was a reduction in the incidence of developing arthritis from
58% in the control group to 17% in the Perna group [17].
In the mouse with established arthritis, Perna had no eﬀect
on the arthritis scores after 10 days, but reduced the score by
day 81 [17].
4.3. Zymosan-Induced Inﬂammation. Zymosan is commonly
used as a local irritant to cause acute inﬂammation. Pen-
toxifylline acts to reduce the levels of the inﬂammatory
interleukins and TNF-α. Lyprinol had an additive eﬀect with
pentoxifylline in rat zymosan models of arthritis. Thus, in
zymosan-inducedpawswelling,pentoxifylline(125mgkg−1)
and Lyprinol (20mgkg−1) alone reduced paw swelling by
15–20%, and in combination by about 50% [20].
4.4. Mycobacterium tuberculosis. When chronic polyarthritis
was induced in rats using adjuvant, prepared from dried
M. tuberculosis, inoculated into the tailbase, Lyprinol pre-
treatment (20mgkg−1 with continued treatment) reduced
paw swelling [12]. The level of swelling in the front and
rear paw group after adjuvant treatment was 2.8mm and
1.2mm, and this was reduced to 1.4mm and 0.23mm,
respectively, by Lyprinol [12]. Lyprinol 20mgkg−1 had a
greater eﬀect in reducing paw swelling in this model of
arthritis than the standard non-steroidal anti-inﬂammatory
agents: aspirin (300mgkg−1), ibuprofen (40mgkg−1)o r
naproxen (25mgkg−1)[ 12].
When arthritis was induced in rats using adjuvants
prepared from dried M. tuberculosis, Lyprinol alone at
20mgkg−1 had little eﬀect, and the glucocorticoid pred-
nisoneat2.5or10mgkg−1 hadnoeﬀectalone[19].Thissug-
gests that this is a relatively glucocorticoid-insensitive model
of arthritis. However, when the lower dose of prednisone
was combined with Lyprinol there was a reduction in paw
swelling, and this reduction was greater than with Lyprinol
alone [19]. The COX inhibitors, aspirin (200mgkg−1),
diﬂunisal (80mgkg−1) and mefenamic acid (150mgkg−1)
were also ineﬀective alone in this model, but were eﬀective
when combined with Lyprinol 20mgkg−1 [19]. The free
fatty acids of P. canaliculus mussel powder at 30mgkg−1
have recently been to have a similar ability to piroxicam
(2mgkg−1) to reduce the swelling induced by adjuvants
prepared from dried M. tuberculosis [21].
Pain was the main focus of a study where arthritis was
induced in rats by injecting Freund’s complete adjuvant con-
taining M. butyicum into the hind paw, Lyprinol 25mgkg−1
reduced the swelling [16]. Associated with this reduction in
swelling, there was initially a similar reduction in pain score
(vocalizations during ﬂexions of the paw) with Lyprinol
and naproxen (20mgkg−1)[ 16]. The pain reduction was
maintained in the presence of naproxen but not Lyprinol
[16]. In splenocytes from this model at 14 days, Lyprinol and
naproxen treatment were associated with a similar reduced
ability of LPS to stimulate TNF-α and IFN-γ [16].
Pentoxifylline (125mgkg−1) and Lyprinol (20mgkg−1)
alone had no signiﬁcant eﬀect on the swelling in pre-
establishedM.tuberculosisinducedarthritistoasmallextent,
induced arthritis, whereas in combination the swelling was
reduced to a small extent [20].
5.LyprinolinOther AnimalModels ofDisease
There is some preliminary evidence that Lyprinol may
be potentially useful in ameliorating the symptoms of
inﬂammatory bowel disease. Thus, in a mouse model of
inﬂammatory bowel disease induced by dextran sulphate
sodium, Lyprinol (Pharmalink International) 5mg per day
reduced body weight loss, decreased disease activity in the
colon, and reduced the distal colon crypt area losses [22].
Intestinal mucositis is a common and debilitating side
eﬀect of some kinds of chemotherapy including that with 5-
ﬂuorouracil. In a rat model where 5-ﬂuorouracil was used
to cause intestinal mucositis, Lyprinol prevented weight loss
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Lyprinol has also been shown to reduce the contractions
of the isolated rat uterus, and it has been suggested that it
may be useful for the treatment of dysmenorrhoea [24]. An
advantage Lyprinol had over the NSAIDs (aspirin, ibuprofen
and naproxen), was that it did not induce gastric lesions in
rats [24].
6.Studiesof LyprinolinDogs withArthritis
Studies have shown that Lyprinol is eﬀective in treating
dogs with arthritis. In 2001, it was shown that when dogs
with osteoarthritis were fed with P. canaliculus, there was
an improvement compared to untreated dogs [25]. Three
placebo-controlled studies involving 96 arthritic dogs were
undertaken where the Perna (450, 750 and 1000mg for
dogs <25, 25–34 and >34kg, respectively) was added to
the top of standard food, incorporated into a treat or
incorporated into the food [25]. All the studies had similar
ﬁndings; showing that after 6 weeks, compared to placebo,
Lyprinolwasbeneﬁcial.Arthritisscoreswereofmobility,and
the pain, swelling and crepitus of individual joints and of
each limb. When P. canaliculus was added to the standard
food, it reduced the scores compared to the untreated dogs
[25]. When the individual items of the arthritis scores were
separated, it was shown that there was a major decrease in
the pain score and a modest reduction in joint swelling and
crepitus [25].
However, these results were not substantiated in a 12-
week trial comparing Green shell mussel powder (11mg)
to chondroitin sulphate and placebo in 58 dogs with
degenerative joint disease of the shoulder, elbow, hip joints,
and/or stiﬂe [26]. Both owners and veterinarians reported a
slight improvement of the symptoms in all three groups (i.e.
including the placebo group) [26]. It has been suggested that
the mussel extract was ineﬀective in this study due to the low
dose [27].
A further study showed that at 125mg, Green lipped
muscle extract was eﬀective in dogs with degenerative joint
disease [27]. This trial used 81 lame dogs, compared the
mussel extract to placebo, and assessed the severity of
musculoskeletal dysfunction [27]. Although there was no
improvement after 28 days, by 56 days, 67% of the lame dogs
were showing improvement in the mussel group, compared
to41%intheplacebogroup[27].However,byday112,there
was no signiﬁcant diﬀerence between the groups [27]. No
adverse eﬀects or toxicity was noted with the mussel extract
in dogs [27].
In 2007, Perna was compared to placebo and the non-
steroidal anti-inﬂammatory drug carprofen in 45 dogs with
chronic pain due to osteoarthritis [28]. In this study,
the placebo group showed a 20–40% improvement in
pain/chronic pain, the veterinary mobility index, locomo-
tion, and force exerted by the most eﬀected leg, after 8
weeks [28]. The pain VAS improved by 67% with Perna
and 86% with the non-steroidal anti-inﬂammatory drug
carprofen [28]. Carprofen was also more eﬀective than
Perna in improving the force exerted by the leg (67%
versus 47%; placebo 27%) [28]. Perna and carprofen caused
similar improvements in chronic pain (80%; placebo, 20%)
and the veterinary mobility index (67%; placebo, 27%)
[28].
7.ClinicalTrialswithLyprinolinHumans
Clinical trials of the eﬀects of Lyprinol in subjects with
arthritis and asthma have been reported, and are described
in this section. The question, this part of the review
asks, is whether Lyprinol has been shown to be anti-
inﬂammatory in humans? After searching and collecting
all the information found on Pubmed and the Internet
for Lyprinol/Seatone/Perna from 1990 onwards, the clinical
trials in inﬂammation were selected, and all of these are
reviewed. Most of the clinical trials with Lyprinol have ﬂaws.
It was decided not to exclude any of these, but to present
the results of each clinical trial in sequence, with a discussion
of any problems with the methodology and interpretation of
results in the trial.
To my knowledge, there are no ongoing clinical trials
with Lyprinol. Some clinical trials that have previously
been reported to be in progress (Crohn’s disease, ulcerative
colitis, lupus, psoriasis), but have not been reported. The
clinical trials presented show that there is some evidence that
Lyprinol may have a small eﬃcacious eﬀect in osteoarthritis
and rheumatoid arthritis.
7.1. Osteoarthritis and Rheumatoid Arthritis. In 1998, the
eﬀects of the stabilized green-lipped mussel powder 1150mg
per day (ﬁve capsules, Group A) was compared to that
of the lipid extract 210mg per day (three capsules, Group
B) in subjects with osteoarthritis and rheumatoid arthritis
at the outpatients’ clinic of the Glasgow Homoeopathic
Hospital [29]. Both groups (A and B) had 15 subjects with
osteoarthritis and 15 subjectswith rheumatoid arthritis [29].
Most of the subjects with osteoarthritis were taking non-
steroidal anti-inﬂammatory drugs, while half of the subjects
with rheumatoid arthritis were taking second line drugs
[29], which were not speciﬁed. In osteoarthritis, there were
improvements after 3 months of articular index, morning
stiﬀness and functional index with both preparations. Thus,
insubjectswithosteoarthritisinGroupA,thearticularindex
decreased from a baseline of 9.5 to 4.3, morning stiﬀness
from 52.5 to 24.3, and the functional index from 10.4 to
4.8 [29]. In subjects with rheumatoid arthritis in Group
A, articular index decreased from a baseline of 14.8 to 5.9,
morning stiﬀness from 98.4 to 27.1, and the functional index
f r o m1 2 . 9t o6 . 9[ 29]. Similar results for these parameters
were obtained in Group B. Similar reductions in pain scores
were obtained in the subjects with osteoarthritis in Group
A (6.1 to 4.8) and Group B (6.1 to 5.0), but this was only
signiﬁcant in Group B [29]. In rheumatoid arthritis, both
preparations of Lyprinol improved articular index, morning
stiﬀness and functional index to a similar extent as in
osteoarthritis, and there was no signiﬁcant improvement in
pain scores [29]. Neither preparation improved grip strength
in the right or left hands of subjects with either osteoarthritis
or rheumatoid arthritis [29].
A major ﬂaw in this trial was that there was not a placebo
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eﬀects of the Lyprinol were greater than the placebo eﬀect.
The authors argue that the placebo eﬀect is small in arthritis
[29], but without a placebo group we cannot tell whether
this would have been so in this protocol. Recent placebo-
controlled trials suggest that there is about a 20% reduction
in osteoarthritis symptoms with placebo. Thus, in a 12-week
placebo-controlled trial of tramadol in osteoarthritis of the
knee, there was about a 20% reduction in pain, stiﬀness and
physical function with placebo [30]. In trials of diacerein
and othokin in osteoarthritis, the placebo also reduced pain
by about 20% at 3 months [31, 32]. The reductions in
articular index, morning stiﬀness and functional index with
the mussel powder or lipid extract were about 55%, which
(if we accept 20% as the placebo level) suggests that Lyprinol
doeshavebeneﬁtsonthesesymptoms.Lyprinolreducedpain
by 20% in the clinical trial with the mussel powder or lipid
extract [29], which is comparable to the placebo eﬀect in
placebo-controlled trials in osteoarthritis. This suggests that
Lyprinol is having little or no eﬀect on the pain associated
with osteoarthritis.
7.2. Osteoarthritis. There was another study suggesting that
Lyprinol was eﬀective in relieving the pain osteoarthritis,
published in 2003. All54 patients hearddetailed information
aboutLyprinol,andweretreatedwithLyprinol(twocapsules
bid) [33]. After 8 weeks, of 56 subjects with hip and knee
osteoporosis, there was a reduction in pain from 6.4cm on
the Visual Analogue Scale to 3.9 [33], a 39% reduction. A
similar percentage beneﬁt was observed with Lyprinol in
joint function [33]. At 8 weeks, 87% of patients and 90% of
doctors reported improved in global assessment [33].
To be properly controlled, this clinical trial should have
provided information to all participants about placebo, and
compared Lyprinol with a control group receiving a placebo.
Without this control group it is diﬃcult to determine
whether Lyprinol was eﬀective, or it was a combination of
the information and placebo eﬀect that was eﬀective in the
group treated with Lyprinol. There is also a discrepancy
between this study showing a reduction in pain of 39% with
Lyprinol in osteoarthritis [33] to the previous study showing
a reduction in pain of 20% (discussed in previous section
[29]), which is equivalent to the placebo response. There are
several possible reasons for this discrepancy. For instance,
the doses of Lyprinol are not in the same range but not
identical in the two studies, and the length of the studies are
diﬀerent (3 months versus 8 weeks). Another reason for the
discrepancy could be that there was a positive response to the
information in the Lyprinol group.
The ﬁnal trial of Lyprinol in osteoarthritis was placebo-
controlled and reported in 2004 [33]. In this trial, 80 subjects
with knee osteoarthritis were randomized on a double-blind
manner to Lyprinol or placebo [34]. Pain scores decreased
in both groups, and were lower for Lyprinol than placebo
after 8 and 12 weeks (VAS of ∼51mm versus 57mm at
both time points), but not 18 weeks (VAS of ∼53 versus 56)
[34].Thepatients’globalassessmentoftheirarthritisshowed
improvement in both groups, and was only signiﬁcant
greater for Lyprinol after 12 (2.8 versus 3.2 in the placebo
group) and 18 weeks (3.0 versus 3.1) [34]. However, there
was no diﬀerence in the physicians’ global assessment of
arthritis between groups [34]. In this study, the reductions
in pain scores and the patients’ assessment of improvement
with Lyprinol were quite small. Also, as both groups were
allowed to take unlimited paracetamol, there was great
variability in the intake of paracetamol in both groups
calculated as a percentage of baseline intake [34]. Without
the absolute amounts of paracetamol taken by the subjects,
it diﬃcult to assess whether paracetamol contributed to the
small reduction in pain observed with Lyprinol.
7.3. Rheumatoid Arthritis. Lyprinol in combination with
ﬁsh oil has been tested in 50 adults with rheumatoid joint
disorder, moderate pain and morning stiﬀness [35]. After 12
weeks of treatment, the mean duration of morning stiﬀness
was reduced from 13.7 to 12.4min, the number of painful
joints from 4.18 to 3.58, and the number of swollen joints
from 2.62 to 1.94 by the combination of Lyprinol and
ﬁsh oil [35]. Pain was evaluated separately by the patients
and physicians, and was also reduced with the combination
treatment [35].
The two most obvious criticisms of this study, is that
there was no placebo group, and thus we do not know
whether the small beneﬁts observed were a placebo response
or due to the combination of Lyprinol and ﬁsh oil. Secondly,
if we concede that there may be a small beneﬁcial response,
we cannot determine whether it is due to Lyprinol, ﬁsh oil
or the combination? For instance, if ﬁsh oil was eﬀective, and
Lyprinol was not, the combination could still show beneﬁt.
7.4. Asthma. A small clinical trial suggests that Lyprinol may
be useful against some of the symptoms of atopic (allergic)
asthma. The 46 subjects in this trial has mild asthma with
symptoms twice a week or less with a FEV1 (the forced
expiratory volume in one second) of ≥80% of predicted,
and were using short-acting β-adrenoceptor agonists for
symptom relief [36]. Subjects receive either two tablets bid
of either Lyprinol or placebo for 8 weeks. Lyprinol reduced
daytime wheeze and improved morning peak expiratory
ﬂow, but did not improve night awakenings, use of β-
agonists, or FEV1 [36]. It was suggested that the FEV1 was
quite high in these subjects, and diﬃcult to improve [36].
Glucocorticoids improve FEV1 in subjects with asthma.
Thus, it seems unlikely that Lyprinol will replace the steroids
in the treatment of mild asthma. A clinical trial determining
the eﬀect of Lyprinol on the FEV1 in subjects with more
severe asthma would be on interest. One point in favour of
the use of Lyprinol is that the small beneﬁts come with no
excess of adverse eﬀects [36].
In their labelling, Blackmores have emphasized that
there is good clinical evidence that Lyprinol causes a small
improvement in lung function, rather than any beneﬁcial
eﬀects in arthritis. This labelling is supported by the clinical
trials with Lyprinol reported here.
8. StudiesComparing the Anti-Inﬂammatory
Effects of LyprinolandFishOil
EPA and DHA are the main constituents of ﬁsh oil sup-
plements. Fish oil is probably anti-inﬂammatory because,6 Evidence-Based Complementary and Alternative Medicine
like Lyprinol, it inhibits the production of eicosanoids and
cytokines[37].Recently,adirectcomparisonofLyprinoland
ﬁshoilpreparations(Blackmore’s),availableinAustralia,has
shown EPA (1μgmL −1) inhibits COX-1 and COX-2 by 92%
and 91%, and DHA inhibits by 65% and 95%, respectively
[13]. These values are mainly higher than the inhibition
observed with Lyprinol and its free fatty acid extracts (values
given previously), probably because the levels of EPA and
DHA in Lyprinol are lower than in preparations of EPA or
DHA [13] .H o w e v e r ,w h e nL y p r i n o li sh y d r o l y s e di th a sa
similar ability to inhibit the COX enzymes as ﬁsh oil [13].
Theevidencethatﬁshoilisanti-inﬂammatorywhenused
clinically as an adjunct in rheumatoid arthritis is quite good
[38]. However, the evidence for clinical eﬃcacy for ﬁsh oil in
osteoarthritis and asthma is weak [37].
There is a clinical trial showing that the combination of
Lyprinol, EPA, and DHA are eﬀective and well-tolerated in
the treatment of rheumatoid arthritis [34]. Unfortunately,
theeﬀectsofthecombinationwerenotcomparedtoLyprinol
alone,orEPA/DHAalone,inthisstudy,makingitimpossible
to determine whether any of the beneﬁt was due to Lyprinol,
or whether Lyprinol has added beneﬁts to EPA/DHA. Thus,
head to head trials of Lyprinol and ﬁsh oil should be
undertaken in subjects with rheumatoid arthritis, preferable
with a placebo group.
In a mouse model of inﬂammatory bowel disease, Lypri-
nol 5mg/day prevented body weight loss whereas EPA/DHA
55mg/day did not [22]. Lyprinol was also more eﬀective
than the EPA/DHA in reducing disease activity index, which
included body weight loss, rectal bleeding, stool consistency,
and overall condition [22]. Lyprinol increased the crypt area
index, whereas EPA/DHA did not [22]. To date, the clinical
trials of Lyprinol in inﬂammatory bowel disease have not
been reported. Clinical trials of ﬁsh oil in Crohn’s disease
[39] and ulcerative colitis [40] have not shown clear cut
beneﬁts. A clinical trial of Lyprinol alone in inﬂammatory
bowel disease is indicated.
In summary, there is weak evidence that ﬁsh oil and
Lyprinol have a small beneﬁt in osteoarthritis, rheumatoid
arthritis, and asthma, and as clinical anti-inﬂammatory
agents there is little to choose between them. Fish oil does
have the beneﬁt of being antithrombotic, and reducing the
incidence of coronary heart disease and stroke. Thus, in
subjectswitharthritisathighcardiovascularrisk,ﬁshoilmay
have a better overall eﬀect than Lyprinol.
9. Conclusion
The experimental evidence that Lyprinol has anti-inﬂam-
matory eﬀects is good, and consequently it may work in
humans. There is lot of hype about the clinical uses of
Lyprinol on the Web (and in the wider media over the
years), but much of it is not supported by good clinical
trials. Appropriate clinical trials have not been undertaken.
For instance, both randomized, double-blind, placebo-
controlled trials and comparator trials with standard drugs
needtobeundertaken,withLyprinolinrheumatoidarthritis
and osteoarthritis. Without good clinical trials, we cannot
conclude that Lyprinol is eﬀective or ineﬀective in human
inﬂammation. No adverse eﬀects have been reported with
Lyprinol. Thus, although it is diﬃcult to conclude from the
completed clinical trials whether it does much good, it can
be concluded that Lyprinol probably does no harm.
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